Data Presentation for FDA Submissions: Text and Tabular Exposition

Over the years, representatives of both the FDA and the pharmaceutical industry have published in pharmaceutical journals or presented at work-shops many helpful suggestions to facilitate NDA review of submissions and to avoid elements that impede the review. Several authors and presenters have expressed the FDA reviewers’ frustration at having to review a submission that is incoherently assembled or confusing in its presentation.